Redefining patient care with new targeted therapies and devices, the field of dermatology is an exciting and constantly evolving place for robust clinical research and development. With a population that is aging and more health-conscious than ever before, the expertise level of dermatology clinical trials is at its all-time high and novel pharmacological agents are being discovered and developed annually.
One of the newest areas of research in therapeutics are Janus kinase (JAK) inhibitors. Drugs such as tofacitinib and ruxolitinib are already being used in the treatment of rheumatoid arthritis, although current clinical research is already focused on JAK inhibitors potential in treating various skin diseases such as vitiligo, psoriasis and hair loss. Early phase clinical trials are already rolling out, with JAK inhibitors showing a huge promise, that soon skin conditions such as psoriasis and atopic dermatitis will be controlled, whether the diseases will occur in a moderate or severe way.
While there are plenty reasons of red-colored and itchy skin, eczema is the one name to combine all these inflammatory skin conditions. Currently, the standard treatment is a combination of moisturizers and special bathing practices, topical corticosteroids and calcineurin inhibitors, antimicrobials and antiseptics. Nevertheless, eczema clinical trials are still widely pursued to discover even better drug combinations, to achieve better treatment results in children eczema, and to develop novel drug substances that would lead to a breakthrough in dermatology.
New technologies are focusing on the improvement of care for skin cancer (particularly melanoma), especially when it comes to better diagnosis and monitoring. These include photo-acoustic tomography (PAT) which may prevent invasive excisions and the application of Artificial Intelligence (AI) in diagnostics. Only by adapting the latest technologies in dermatology clinical trials, we can reduce melanoma morbidity rates.
